Short answer
Akebia Therapeutics, Inc. (AKBA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $54M (down 6.6% year over year) with net income of −$9M.
Q1 2026 key financials · XBRL
- Revenue
- $54M
- −6.6% YoY
- Net income
- −$9M
- −248.1% YoY
- Operating margin
- -8.8%
- EPS (diluted)
- −$0.03
- −200.0% YoY
Source: XBRL data from the Akebia Therapeutics, Inc. (AKBA) Q1 2026 10-Q on SEC EDGAR. USD.
Akebia Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Vafseo access approximately 290,000 U.S. dialysis patients by March 2026
- Auryxia revenue headwind from Teva generic entry after March 11, 2026 approval
- $1.8 billion cumulative R&D expenses through March 31, 2026
- AKB-097 Phase 2 basket study expected in second half of 2026
Risk Factors
- Profitability risk: net loss $9.1 million in Q1 2026 and accumulated deficit $1.7 billion
- Vafseo commercialization risk: WCF royalty payments of 8%–14% of U.S. net sales through May 31, 2028
- Regulatory risk: Vafseo approval limited to dialysis patients after FDA’s March 2022 complete response letter
- Competitive risk: Auryxia lost exclusivity in March 2025, exposing revenue to generic competition
- Pipeline investment risk: AKB-097 requires milestone payments up to $94.5 million for development and regulatory events
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Akebia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.